: News

Filed Under:

Police Shooting In Fairfax Remains A Mystery

Play associated audio

By Kate Sheehy

Fairfax County police officers still don't have an answer as to why an officer shot an unarmed man in the middle of an intersection last month.

Dave Masters was a former member of the elite military unit the "Green Berets," and had a history of mental illness, having been diagnosed with bipolar disorder. According to the Washington Post, last month after Masters took some flowers from the front of a landscaping business, police pulled him over at Route 1 and Forth Hunt Road. What provoked an officer to shoot the 52-year-old Masters through the rear passenger window of his car, killing him, remains a mystery.

The 26-year-old officer who fired his weapon has not been named, but is said to have six years experience on the force. He reportedly remains on restricted duty.

Fairfax police are not releasing any public information regarding motive, the number of shots fired or witness accounts. A Fairfax police spokeswoman tells the Post "it's all part of the ongoing investigation."

NPR

A Personal History Of L.A. Punk: 'It Was A Free-For-All For Outcasts'

John Doe, Exene Cervenka and Dave Alvin of X join Fresh Air to discuss punk's early days. "Anybody could belong to punk that wanted to be there," Cervenka says. "[It] didn't matter how old you were."
NPR

'Touch Tours' Help Blind Experience Philadelphia's Historic Food Scene

A hands-on tour of Philadelphia's historic Italian Market includes time to appreciate the scents and sounds — and opportunities to sample the district's delicious chocolate, cheeses and fresh pastas.
NPR

WATCH: Ted Cruz Clashes With Trump Supporter, 'He Is Playing You For A Chump'

It wasn't the only unfortunate incident that befell Ted Cruz's campaign over the weekend as he's struggling to catch Donald Trump ahead of Tuesday's crucial vote.
NPR

Biotech's Theranos Offers A Cautionary Tale For Silicon Valley

The blood-testing startup led by Elizabeth Holmes soared on hype and celebrity boosters. Now it's under federal scrutiny. It could show that Silicon Valley's success model doesn't work in biotech.

Leave a Comment

Help keep the conversation civil. Please refer to our Terms of Use and Code of Conduct before posting your comments.